
---
title: '治疗有害细菌的新药_耐药感染的新抗生素候选者'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/22/201540nahtaah15fh79vav.jpg'
author: 科学网
comments: false
date: Fri, 22 Apr 2022 20:18:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/22/201540nahtaah15fh79vav.jpg'
---

<div>   
<p style="line-height: 3em;"><span style="font-family: "times new roman"; font-size: 24px;"><span style="font-family: "times new roman";">治疗有害细菌的新药</span>:<span style="font-family: "times new roman";">耐药感染的新抗生素候选者</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em; text-align: center;"><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" target="_blank"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/22/201540nahtaah15fh79vav.jpg" title alt="Soil-Hands-Dirt-777x518.jpg" referrerpolicy="no-referrer"></span></a></p><p style="line-height: 2em;"><span style="font-family: "times new roman"; font-size: 18px;">Fig. 1 </span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" target="_blank"><span style="font-family: "times new roman"; font-size: 18px; color: #454545; background: white;">Scientists discovered a potential candidate for antibiotic drug development in a soil bacterium known as <em><span style="border: 1px none windowtext; padding: 0px;">Lentzea flaviverrucosa</span></em>.</span></a></p><p style="line-height: 2em; text-align: center;"><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" target="_blank"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202204/22/201626wuokwuwhte266wzp.jpg" title alt="Joshua-Blodgett-777x518.jpg" style="color: rgb(69, 69, 69); font-family: "times new roman"; font-size: 18px;" referrerpolicy="no-referrer"></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Fig. 2 <a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" target="_blank"><span style="font-family: "times new roman"; font-size: 18px; color: #454545; background: white;">Joshua Blodgett, Assistant Professor of Biology, Washington University in St. Louis. Credit: Sean Garcia, Washington University</span></a></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国圣路易斯华盛顿大学（</span><a href="https://scitechdaily.com/tag/washington-university-in-st-louis/" style="font-size: 18px; font-family: "times new roman";" target="_blank">Washington University in St. Louis</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）</span>2022<span style="font-family: 宋体;">年</span>4<span style="font-family: 宋体;">月</span>19<span style="font-family: 宋体;">日提供的消息，美国和阿根廷（</span>Argentina<span style="font-family: 宋体;">）的研究人员合作，在一种被称为</span><em><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" target="_blank">Lentzea flavaviverrucosa</a></em>的土壤细菌中发现了一种潜在的抗生素药物开发候选物质（</span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" style="font-size: 18px; font-family: "times new roman";" target="_blank">New Drugs for Bad Bugs: From Rare Soil Microbe, a New Antibiotic Candidate for Drug-Resistant Infections</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）。相关研究结果于</span>2022<span style="font-family: 宋体;">年</span>4<span style="font-family: 宋体;">月</span>19<span style="font-family: 宋体;">日已经在《美国国家科学院院刊》（</span></span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119" style="font-size: 18px; font-family: "times new roman";" target="_blank">Proceedings of the National Academy of Sciences</a><span style="font-size: 18px; font-family: "times new roman";">简称</span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119" style="font-size: 18px; font-family: "times new roman";" target="_blank">PNAS</a><span style="font-size: 18px; font-family: "times new roman";">）网站发表——</span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con1" style="font-size: 18px; font-family: "times new roman";" target="_blank">Chunshun Li</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con2" style="font-size: 18px; font-family: "times new roman";" target="_blank">Yifei Hu</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con3" style="font-size: 18px; font-family: "times new roman";" target="_blank">Xiaohua Wu</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con4" style="font-size: 18px; font-family: "times new roman";" target="_blank">Spencer D. Stumpf</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con5" style="font-size: 18px; font-family: "times new roman";" target="_blank">Yunci Qi</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con6" style="font-size: 18px; font-family: "times new roman";" target="_blank">John M. D’Alessandro</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con7" style="font-size: 18px; font-family: "times new roman";" target="_blank">Keshav K. Nepal</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con8" style="font-size: 18px; font-family: "times new roman";" target="_blank">Ariel M. Sarotti</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con9" style="font-size: 18px; font-family: "times new roman";" target="_blank">Shugeng Cao</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con10" style="font-size: 18px; font-family: "times new roman";" target="_blank">Joshua A. V. Blodgett</a><span style="font-size: 18px; font-family: "times new roman";">. Discovery of unusual dimeric piperazyl cyclopeptides encoded by a Lentzea flaviverrucosa DSM 44664 biosynthetic supercluster. </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119" style="font-size: 18px; font-family: "times new roman";" target="_blank">Proceedings of the National Academy of Sciences</a><span style="font-size: 18px; font-family: "times new roman";">, April 19, 2022, 119 (17): e2117941119. DOI: </span><a href="https://doi.org/10.1073/pnas.2117941119" style="font-size: 18px; font-family: "times new roman";" target="_blank">10.1073/pnas.2117941119</a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119" style="font-size: 18px; font-family: "times new roman";" target="_blank">https://www.pnas.org/doi/10.1073/pnas.2117941119</a><span style="font-size: 18px; font-family: "times new roman";">.</span><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">参与此项研究的有来自美国夏威夷大学希洛分校（</span>University of Hawaii at Hilo<span style="font-size: 18px; font-family: 宋体;">）、夏威夷大学癌症中心（</span> University of Hawaii Cancer Center<span style="font-size: 18px; font-family: 宋体;">）、圣路易斯华盛顿大学、芝加哥大学（</span>The University of Chicago<span style="font-size: 18px; font-family: 宋体;">）以及阿根廷的罗萨里奥国立大学（</span>Universidad Nacional de Rosario, Argentina<span style="font-size: 18px; font-family: 宋体;">）的研究人员。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">随着耐药性和新出现的感染成为日益严重的全球健康威胁，对新型抗生素的需求正在激增。研究人员正在竞相重新检查一组被称为放线菌（</span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">actinomycetes</span></a><span style="font-size: 18px; font-family: "times new roman";">）的微生物，它们是我们最成功的治疗方法之一。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">圣路易斯华盛顿大学文理学院生物系生物系助理教授、此研究的共同通讯作者约书亚·布洛杰特（</span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con10" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Joshua A. V. Blodgett</span></a><span style="font-size: 18px; font-family: "times new roman";">, Fig. 2<span style="font-size: 18px; font-family: 宋体;">）说：“稀有放线菌是新的生物活性化合物的未充分开发的来源。我们基于基因组学的方法使我们能够识别一种不同寻常的肽，用于未来的药物设计工作。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">放线菌产生的生物活性成分构成许多临床有用药物的基础，特别是抗生素和抗癌药物。自</span>20<span style="font-size: 18px; font-family: 宋体;">世纪</span>40<span style="font-size: 18px; font-family: 宋体;">年代以来，制药公司分析了许多常见的放线菌，看看它们可能产生什么。如今，医院和诊所使用的所有抗生素中约有三分之二部分来自放线菌。但其中一些微生物——被称为稀有放线菌</span>( </span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">rare actinomycetes</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 11px; font-family: Georgia; background: white;">)</span><span style="font-size: 18px; font-family: 宋体;">——已经被编入目录，但到目前为止还没有进行广泛的研究。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">“稀有”的定义并不是固定不变的，但这些放线菌往往比其他真菌更难在自然界中找到，而且它们可能生长得更慢，约书亚·布洛杰特说。由于这些和其他原因，许多罕见的放线菌还没有被完全鉴定为药物发现和生物技术目的。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">约书亚·布洛杰特说，在罕见的放线菌中，</span><em><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" target="_blank">Lentzea flavaviverrucosa</a></em><span style="font-size: 18px; font-family: 宋体;">脱颖而出。他说</span>:<span style="font-size: 18px; font-family: 宋体;">“它具有不同寻常的生物学特性，编码了不同寻常的酶学特性，推动了意想不到的化学反应的产生，所有这些都隐藏在一个很大程度上被忽视的细菌群中。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">约书亚·布洛杰特和他的合作者，包括夏威夷大学的共同通讯作者曹树耿</span>(</span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119#con9" style="font-size: 18px; font-family: "times new roman";" target="_blank">Shugeng Cao</a>音译<span style="font-size: 18px; font-family: "times new roman";">)<span style="font-family: 宋体;">，发现这种罕见的放线菌产生的分子对某些类型的人类卵巢癌、纤维肉瘤、前列腺癌和白血病细胞系具有活性。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">科学家们最初发现</span><em><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" target="_blank">Lentzea flavaviverrucosa</a></em>是在寻找稀有放线菌时发现的，这种放线菌的基因特征表明它们可以制造胡椒基分子（</span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">piperazyl molecules</span></a><span style="font-size: 18px; font-family: "times new roman";">）。约书亚·布洛杰特说，这些分子包含了一种不寻常的组成部分，这是潜在的类似药物活性的标志。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">但随着研究人员深入挖掘，他们发现了一些其他的惊喜。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">约书亚·布洛杰特说：“从高水平上看，似乎基因组的一个区域可能会产生两种不同的分子。这只是有点奇怪。通常我们会想到基因簇，一组基因就像制造单个类药物分子的蓝图。但在这个单簇中，预测似乎存在有太多的化学成分。”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">早期的线索被证明是准确的。使用现代代谢组学与化学和结构生物学技术的结合，约书亚·布洛杰特和他的团队能够证明这种罕见的放线菌实际上从一组被称为超簇（</span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">supercluster</span></a><span style="font-size: 18px; font-family: "times new roman";">）的基因中产生了两种不同的生物活性分子。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">超簇（</span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Superclusters</span></a><span style="font-size: 18px; font-family: "times new roman";">）在生物学中很少见。这种特殊的超簇编码了两种不同的分子，这些分子后来在一个非典型的化学反应中被紧密结合在一起。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">“大自然将两种不同的东西结合在一起，”约书亚·布洛杰特说，“事实证明，针对几种不同的癌细胞株，当你把</span>A<span style="font-size: 18px; font-family: 宋体;">和</span>B<span style="font-size: 18px; font-family: 宋体;">结合在一起时，它会变成更有效的东西。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://scitechdaily.com/new-drugs-for-bad-bugs-from-rare-soil-microbe-a-new-antibiotic-candidate-for-drug-resistant-infections/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "arial black", "avant garde";"><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119" target="_blank">Significance</a></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Actinomycetes produce many clinically useful drugs, especially antibiotics and anticancer agents. Rare actinomycetes are known to produce bioactive molecules but they remain underexplored compared to more common <em>Streptomyces spp</em>. Natural molecules having piperazate building blocks are often bioactive, and genome analyses previously indicated the rare actinomycete <em>Lentzea flaviverrucosa</em> DSM 44664 may encode for the production of such molecules. To discover these from complex fermentation mixtures, we devised and employed a targeted metabolomic approach that revealed petrichorin A, an unusual heterodimeric biaryl-cyclohexapeptide. Its structure was determined by using multi-dimensional nuclear magnetic resonance, theoretical calculations, and strain mutagenesis, and its biosynthesis implicated an atypical cytochrome p450 heterodimerization event. Petrichorin A demonstrated potent cytotoxicity, highlighting heterodimeric-biaryls as interesting features for future drug design.</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "arial black", "avant garde";"><a href="https://www.pnas.org/doi/10.1073/pnas.2117941119" target="_blank">Abstract</a></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Rare actinomycetes represent an underexploited source of new bioactive compounds. Here, we report the use of a targeted metabologenomic approach to identify piperazyl compounds in the rare actinomycete <em>Lentzea flaviverrucosa</em> DSM 44664. These efforts to identify molecules that incorporate piperazate building blocks resulted in the discovery and structural elucidation of two dimeric biaryl-cyclohexapeptides, petrichorins A and B. Petrichorin B is a symmetric homodimer similar to the known compound chloptosin, but petrichorin A is unique among known piperazyl cyclopeptides because it is an asymmetric heterodimer. Due to the structural complexity of petrichorin A, solving its structure required a combination of several standard chemical methods plus in silico modeling, strain mutagenesis, and solving the structure of its biosynthetic intermediate petrichorin C for confident assignment. Furthermore, we found that the piperazyl cyclopeptides comprising each half of the petrichorin A heterodimer are made via two distinct nonribosomal peptide synthetase (NRPS) assembly lines, and the responsible NRPS enzymes are encoded within a contiguous biosynthetic supercluster on the <em>L. flaviverrucosa</em> chromosome. Requiring promiscuous cytochrome p450 crosslinking events for asymmetric and symmetric biaryl production, petrichorins A and B exhibited potent in vitro activity against A2780 human ovarian cancer, HT1080 fibrosarcoma, PC3 human prostate cancer, and Jurkat human T lymphocyte cell lines with IC<sub><span style="font-family: "times new roman"; font-size: 9px;">50</span></sub> values at low nM levels. Cyclic piperazyl peptides and their crosslinked derivatives are interesting drug leads, and our findings highlight the potential for heterodimeric bicyclic peptides such as petrichorin A for inclusion in future pharmaceutical design and discovery programs.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-212210-1335186.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-212210-1335186.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1334919.html" target="_black">中巴美合作研究表明，手性金纳米颗粒可使疫苗效力提高25%以上</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-212210-1335293.html" target="_black">高压化学：陌生世界合成新型爆炸性化合物</a>                    <!--大赛结束-->
                                        
  
</div>
            